Supply Chain

In this week's Pharma Pulse, lawmakers introduce comprehensive 340B legislation, Peak Rock Capital completes its acquisition of Asembia, and new LogiPharma data shows supply chain risks across the industry.

As China tightens supply chain rules, tariff pressure persists, and the FDA's PreCheck Program takes shape, this FAQ breaks down how pharma reshoring stands in 2026.

Gerren McHam of the API Innovation Center on what a resilient US pharmaceutical supply chain looks like in five to ten years, and what execution actually requires.

The FDA selected seven companies, including two CGT manufacturers, for its PreCheck Pilot to accelerate domestic manufacturing approvals and bolster supply chain resilience.

As CGTs scale from clinical to commercial, Cencora's Krystal Haynes discusses the supply chain decisions that determine whether a launch succeeds.

Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply chain independence from China actually requires.

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions.

In this special episode of Pharma Pulse, Rohit Tripathi breaks down how companies should be scenario planning ahead of the first USMCA joint review which begins on July 1.

The investment adds 27 temperature-controlled freight facilities across the Americas, Europe, and Asia as demand for biologics distribution infrastructure continues to climb.

In this week's Pharma Pulse, Europe’s drug pricing standoff intensifies, CMS moves to formalize Medicare negotiation rules, FDA expands OTC naloxone, and DSV launches a new pharma air route.

As the US and Iran reach a framework agreement to reopen the Strait of Hormuz, Pharmaceutical Commerce breaks down what the deal means for pharmaceutical supply chains.

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

By prioritizing solutions such as reusable plastic pallets, pharmaceutical companies can ensure that their high-value innovations are protected by equally innovative packaging.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

Pharma supply chains are embracing AI, digital twins, IoT, and DSCSA-driven traceability to improve resilience, visibility, and profitability amid rising global disruptions.

Ben Sharples, LogiPharma event director, examines how life sciences organizations are adapting to AI in the supply chain, with expert testimony from LogiPharma partners.

US pharma supply chains are shifting amid regulation and geopolitics, with BIOSECURE driving less Asia reliance and more complex, distributed networks.

Decision intelligence helps pharma unify small molecule and cell and gene therapy supply chains through AI-driven, automated decision-making.

AI-driven cold chain visibility is only as reliable as the data behind it, exposing gaps between compliance, monitoring, and true product conditions.

Nico Vandaele shares how advanced modeling and simulations can be used to get ahead of future supply chain disruptions.

Raquel Vazquez discusses how data can be incorporated to make key decisions within the cold chain.

Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain transformation.

Shawn McGee discusses today's key risks in the pharma supply chain, and how to prevent disruptions.